company background image
CALA

Calithera Biosciences NasdaqGS:CALA Stock Report

Last Price

US$0.38

Market Cap

US$1.8m

7D

-17.4%

1Y

-95.5%

Updated

28 Jan, 2023

Data

Company Financials +

Calithera Biosciences, Inc.

NasdaqGS:CALA Stock Report

Mkt Cap: US$1.8m

CALA Stock Overview

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States.

CALA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

New

Notes are coming soon

Calithera Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Calithera Biosciences
Historical stock prices
Current Share PriceUS$0.38
52 Week HighUS$14.87
52 Week LowUS$0.36
Beta1.33
1 Month Change-87.86%
3 Month Change-85.87%
1 Year Change-95.45%
3 Year Change-99.68%
5 Year Change-99.74%
Change since IPO-99.80%

Recent News & Updates

Calithera gains 16% as FDA awards Fast Track status for lung cancer candidate

Oct 03

Recent updates

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

Aug 17
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Invest In Growth?

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Dec 17
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Aug 27
We Think Calithera Biosciences (NASDAQ:CALA) Needs To Drive Business Growth Carefully

Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

May 02
Is Calithera Biosciences (NASDAQ:CALA) In A Good Position To Deliver On Growth Plans?

What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Mar 10
What Kind Of Investors Own Most Of Calithera Biosciences, Inc. (NASDAQ:CALA)?

Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Jan 17
Calithera Biosciences, Inc. (NASDAQ:CALA) Shares Could Be 46% Below Their Intrinsic Value Estimate

Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Dec 13
Companies Like Calithera Biosciences (NASDAQ:CALA) Are In A Position To Invest In Growth

Shareholder Returns

CALAUS BiotechsUS Market
7D-17.4%0.8%2.8%
1Y-95.5%7.1%-9.2%

Return vs Industry: CALA underperformed the US Biotechs industry which returned 7.1% over the past year.

Return vs Market: CALA underperformed the US Market which returned -9.7% over the past year.

Price Volatility

Is CALA's price volatile compared to industry and market?
CALA volatility
CALA Average Weekly Movement29.9%
Biotechs Industry Average Movement12.2%
Market Average Movement6.9%
10% most volatile stocks in US Market17.3%
10% least volatile stocks in US Market2.8%

Stable Share Price: CALA is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 30% a week.

Volatility Over Time: CALA's weekly volatility has increased from 21% to 30% over the past year.

About the Company

FoundedEmployeesCEOWebsite
201063Susan Molineauxhttps://www.calithera.com

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1.

Calithera Biosciences, Inc. Fundamentals Summary

How do Calithera Biosciences's earnings and revenue compare to its market cap?
CALA fundamental statistics
Market CapUS$1.85m
Earnings (TTM)-US$83.56m
Revenue (TTM)n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CALA income statement (TTM)
RevenueUS$0
Cost of RevenueUS$49.51m
Gross Profit-US$49.51m
Other ExpensesUS$34.05m
Earnings-US$83.56m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-17.18
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did CALA perform over the long term?

See historical performance and comparison